CDKN2A and neoplasm: To our knowledge, such an interaction has not been demonstrated in vascular biology; moreover, it contrasts with interactions described in cancer, wherein β-catenin induces p53 stability and activity through a tumour-suppressor ARF-dependent effect49, or p53 downregulates β-catenin by promoting its degradation50.